The Phase Ib study evaluating the combination of Atezolizumab and Hu5F9-G4 in relapsed or refractory acute myeloid leukemia (AML) was terminated by Hoffmann-La Roche due to the decision to discontinue development for this indication. This outcome suggests potential challenges in the therapeutic efficacy or safety profile of the combination therapy in this patient population. The AML market remains competitive with several emerging therapies, including other immunotherapies and targeted agents. The termination of this trial may impact Roche's positioning in the AML space, necessitating a reassessment of their pipeline and strategic focus on alternative indications or combinations.